Jupiter Neurosciences has dosed the first patient in RESET, a Phase 2a randomized, double-blind, placebo-controlled trial of JOTROL — a micellar trans-resveratrol formulation — in approximately 30 Parkinson's disease patients over 12 weeks. Primary endpoints are safety, tolerability and pharmacokinetics, with exploratory biomarkers covering energy metabolism and inflammation. Phase 1 data reportedly showed increased systemic exposure and measurable cerebrospinal fluid concentrations without serious adverse events.
Key Points
- Phase 2a tests micellar resveratrol in 30 Parkinson's patients
- Phase 1 showed measurable cerebrospinal fluid concentrations, no serious adverse events
- Exploratory endpoints track energy metabolism and inflammation biomarkers
Longevity Analysis
Resveratrol's clinical record has been constrained less by mechanism than by poor absorption and rapid metabolism; confirming central nervous system exposure shifts the question from whether the molecule works to whether it arrives. The biomarker design — mitochondrial energy output and inflammatory signalling — targets the two processes most consistently implicated in neurodegeneration, and in doing so treats Parkinson's as a failure of cellular energy handling rather than a purely dopaminergic deficit. For anyone relying on oral polyphenols, the trial is a reminder that delivery format, not compound selection, often determines whether a supplement reaches the tissue it is meant to support.
Original published by LT Wire.